Instrument NameTeva Pharmaceutical Industries ADRInstrument Symbol(TEVA-N)

Instrument ExchangeNYSE

Three highly successful billionaire money managers are paring down their respective stakes in artificial intelligence (AI) titan Nvidia and purchasing shares of six beaten-down value stocks.

A relatively modest amount of money can go a long way when it's put to work in top-tier businesses with abundant catalysts.

TEVA earnings call for the period ending December 31, 2023.

This mix of growth and value stocks appears set to outperform -- and hopefully makes me a lot richer in the process.

As the third quarter 2023 earnings season ends, it's worth looking back to see which stocks may have been overlooked or mispriced on their results

TEVA earnings call for the period ending September 30, 2023.

You don't need a boatload of cash to begin growing your wealth on Wall Street.

TEVA earnings call for the period ending June 30, 2023.

These stocks should be poised to rebound.

These elite drugmakers are both working through a number of headwinds.

It's unclear whether the pivot will be enough to halt its recent decline.

Investors are reacting positively to Teva's new growth strategy.

TEVA earnings call for the period ending March 31, 2023.

Direct Relief, the National Association of Free and Charitable Clinics (NAFC), and Teva Pharmaceuticals, U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced an expansion of medicine donations through their...

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and MedinCell (Euronext: MEDCL) announced today that the U.S. Food and Drug Administration (FDA) has approved UZEDY (risperidone)...

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and MedinCell (Euronext: MEDCL) announced today that the U.S. Food and Drug Administration (FDA) has approved UZEDY (risperidone)...

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will host an Investor Day on Thursday, May 18, 2023 to launch its new growth strategy and portfolio priorities. The event will take place at the New York Stock...

There's more to the concept of safety than having a business model that looks safe.

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2023 financial results on Wednesday, May 10, 2023 at 7:00 a.m. ET. Following the release, Teva will conduct a...

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) to its partner Alvotech (NASDAQ: ALVO) for the Biologics License Application (BLA) for...

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced six poster abstracts across its neurology portfolio will be presented at the American Academy of Neurology (AAN) Annual Meeting...

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that a respiratory patient monitoring program using data from Teva’s Digihaler System has been implemented within California’s...

You don't need a large pile of money to begin building wealth on Wall Street.

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“ Teva ”) announced today the early tender results in connection with its previously announced tender offers (the “ Offers ”) and that it is increasing the tender caps as specified below...

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816), announced today the launch of additional strengths for the generic version of Revlimid® 1...